Moderna says its COVID-19 vaccine candidate shows high efficacy rate

Moderna says its COVID-19 vaccine candidate shows high efficacy rate
Dado Ruvic/Reuters

For the second time in the span of a week, a pharmaceutical giant has released successful news about a COVID-19 vaccine.

Moderna – a pharmaceutical company that Canada has an agreement with for millions of vaccine doses – has revealed that one of its vaccines is showing some promise amid preliminary trials.

The company revealed Monday morning that one of its vaccine candidate appears to be 94.5 per cent effective in early trials.

“This is a pivotal moment in the development of our COVID-19 vaccine candidate. Since early January, we have chased this virus with the intent to protect as many people around the world as possible. All along, we have known that each day matters. This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,” said Stéphane Bancel, Chief Executive Officer of Moderna.

The news comes one week after Pfizer announced its own vaccine has been 90 per cent effective in preliminary trials.

The United States’ top infectious disease expert, Dr. Anthony Fauci (FOW’-chee), says the news, which follows last week’s announcement by Pfizer of similar results from their vaccine, is a strong step forward in getting control of the pandemic.

Even as health experts celebrate the news, they continue to remind people not to let their guard down in terms of public health measures.

Experts are also predicting that it will take months for doses of any vaccines cleared by the Food and Drug Administration to be widely distributed.


Recent Stories

Send us your news tips and videos!